Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccination, Public Health and Epidemiology
share announcement

Vaccination, Public Health and Epidemiology

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1967

Special Issue Editor

Dr. Ricardo Izurieta

E-Mail Website
Guest Editor
Director Donald Price Center Department of Global Health College of Public Health University of South Florida, Tampa, FL 33620, USA
Interests: vaccine; vaccinology; epidemiology; infectious diseases; public health; emerging infectious diseases; tropical neglected diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the current state of vaccinology as applied to the epidemiology control of infectious diseases, as well as the philosophies, findings, and dynamics of vaccine-preventable diseases and current immunization strategies in the context of public health interventions. In addition to the currently available vaccines, this Special Issue will review new vaccines for emerging and re-emerging diseases, as well as vaccines for neglected tropical diseases. Furthermore, it will address the process of vaccine development, vaccine platforms, and vaccine trials. Papers addressing public health strategies applied to vaccine-preventable disease control are also invited.

Dr. Ricardo Izurieta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • vaccinology
  • epidemiology
  • infectious diseases
  • public health
  • emerging infectious diseases
  • tropical neglected diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 311 KiB  
Article
Mpox Vaccine Hesitancy Among Brazilian Men Who Have Sex with Men: A National Cross-Sectional Study
by Guilherme Reis de Santana Santos, Caíque Jordan Nunes Ribeiro, José Flávio Cerqueira dos Santos Júnior, Valdemar Silva Almeida, Rita de Cassia Dias Nascimento, Nilo Manoel Pereira Vieira Barreto, Anderson Reis de Sousa, Márcio Bezerra-Santos, Lariane Angel Cepas, Ana Paula Morais Fernandes, Isabel Amélia Costa Mendes, Aires Garcia dos Santos Júnior, Maria Luisa Pereira Maronesi and Álvaro Francisco Lopes de Sousa
Vaccines 2024, 12(11), 1229; https://doi.org/10.3390/vaccines12111229 - 29 Oct 2024
Viewed by 855
Abstract
Background: Mpox is a viral zoonosis that has gained increased attention due to a global outbreak in 2022, significantly impacting men who have sex with men (MSM). Vaccination for this disease poses a public health challenge; because it carries a strong stigma, there [...] Read more.
Background: Mpox is a viral zoonosis that has gained increased attention due to a global outbreak in 2022, significantly impacting men who have sex with men (MSM). Vaccination for this disease poses a public health challenge; because it carries a strong stigma, there may be greater hesitancy in vulnerable groups. Objectives: This study aimed to determine the prevalence and factors associated with Mpox vaccine hesitancy among Brazilian MSM. Methods: A cross-sectional study was conducted between September and December 2022 using an online survey targeted at MSM. Recruitment was carried out through social media and dating apps. The sample consisted of 1449 participants and the analysis involved bivariate logistic regression. Results: The prevalence of Mpox vaccine hesitancy was 7.57%. The significant factors associated with hesitancy were primarily related to sexual practices and attitudes towards Mpox exposure and diagnosis, such as not using “glory holes” (aOR: 19.82; 95% CI: 1.60–245.69), reluctance to undergo pre- and post-exposure testing for Mpox (aOR: 9.54; 95% CI: 5.52–16.48), and not knowing close contacts diagnosed with Mpox (aOR: 4.09; 95% CI: 1.72–9.73). Participants who would not take precautions after diagnosis (aOR: 3.00; 95% CI: 1.27–7.07) and those who would not disclose their serological status (aOR: 1.93; 95% CI: 1.13–3.30) also showed a higher likelihood of vaccine hesitancy. Conclusion: Public health strategies should address these factors to expand knowledge about vaccination barriers, plan educational campaigns with targeted messaging for the MSM population, and provide inclusive healthcare environments to increase vaccine acceptance and reduce Mpox transmission in vulnerable groups. Full article
(This article belongs to the Special Issue Vaccination, Public Health and Epidemiology)
10 pages, 811 KiB  
Article
Pertussis Outbreak During 2023 in Gipuzkoa, North Spain
by José María Marimón, Milagrosa Montes, Nahikari Vizuete, Lorea Alvarez Guerrico, Adrian Hugo Aginagalde, Alba Mir-Cros, Juan José González-López and Diego Vicente
Vaccines 2024, 12(10), 1192; https://doi.org/10.3390/vaccines12101192 - 18 Oct 2024
Viewed by 739
Abstract
Background: Pertussis has re-emerged in many countries despite the wide use of vaccines for over 60 years. During 2023, we observed an increase in the incidence of pertussis in Gipuzkoa, north of Spain (with a population of 657,140 inhabitants), mainly affecting children between [...] Read more.
Background: Pertussis has re-emerged in many countries despite the wide use of vaccines for over 60 years. During 2023, we observed an increase in the incidence of pertussis in Gipuzkoa, north of Spain (with a population of 657,140 inhabitants), mainly affecting children between 11 and 15 years of age. Methods: This study included all confirmed cases diagnosed by PCR in nasopharyngeal swab samples. The genome of seven isolates collected in 2023 was sequenced. Results: Between 2018 and 2023, 884 cases of whooping cough were diagnosed. Pertussis incidence (in cases per 100,000 inhabitants) decreased from 36.7 in 2018 to no cases in 2021, increasing again to 56.8 in 2023. In 2023, the age group of 11–15 years old had the highest incidence rate of 409.3. Only 2 of the 56 children < 6 years old required hospitalization, and there were no deaths. The seven isolates collected in 2023 showed the same BPagST-4 (ptxA1/ptxP3/prn2/fim2-1/fim3-1 allelic combination), with all of them expressing the pertactin antigen. Conclusions: Immunity waning after the last dose of vaccination at 6 years old, together with the lack of circulation of Bordetella pertussis during the COVID-19 pandemic, were probably the main reasons for the high increase in the incidence of pertussis in Gipuzkoa in 2023. Full article
(This article belongs to the Special Issue Vaccination, Public Health and Epidemiology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop